304 completed, 135 unknown, 28 recruiting, 15 not yet recruiting. 172 Not applicable, 77 Phase 4, 37 Phase 2, 30 Phase 3, 15 Phase 1.
Follow Coronary Heart Disease: new trials by email Literature Review of Coronary Heart Disease trials Research Report on Coronary Heart Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose, Placebo - Coronary Disease, Coronary Heart Disease | Phase 2 | Not yet recruiting | Venturis Therapeutics, Inc. | 150 | 2027-09-01 | 2026-08-19 |
| Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease Polygenic risk score - Coronary Heart Disease | Not yet recruiting | Medical College of Wisconsin | 200 | 2027-06-01 | 2026-05-04 | |
| Superficial Parasternal Block Combined With Rectus Sheath Block for Open Cardiac Surgery Parasternal and rectus sheath block, ropivacaine 0.25 % - Cardiac Valve Disease, Coronary Heart Disease | Phase 4 | Not yet recruiting | Hôpital du Valais | 100 | 2026-11-01 | 2026-10-22 |
| Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions Intranasal dexmedetomidine, Normal Saline - Coronary Heart Disease, Coronary Artery Disease | Not applicable | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2500 | 2026-09-30 | 2026-09-29 |
| Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity Mazdutide, Placebo - Obesity & Overweight, Coronary Heart Disease | Phase 4 | Recruiting | China National Center for Cardiovascular Diseases | 116 | 2026-09-14 | 2026-10-13 |
| A Cluster-Randomized Controlled Trial AI-powered personalized health report with cardiologist consultation and prescription optimization, Integrated management (follow-up, education, quality control) without AI report and cardiologist consultation - Hypertension, Stroke | Not applicable | Not yet recruiting | Second Affiliated Hospital of Nanchang University | 14400 | 2026-09-10 | 2026-09-28 |
| NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP) Digital health interventions - Type 2 Diabetes, Coronary Heart Disease | Not applicable | Recruiting | University of Eastern Finland | 1400 | 2026-09-01 | 2026-10-06 |
| The Effect of Autonomic Neuropathy Status on the Endpoint Events in Diabetes Patients With Coronary Heart Disease and Sleep Apnea. The total score of Ewing test (i.e. cardiovascular autonomic reflex test and heart rate variability) was ≥1, which was divided into cardiac autonomic neuropathy group (CAN grou - Coronary Heart Disease, Diabetes | Not yet recruiting | Xiangtan Central Hospital | 326 | 2026-08-01 | 2026-07-23 | |
| Intranasal Dexmedetomidine and Perioperative Myocardial Injury Intranasal Dexmedetomidine, Normal saline - Coronary Heart Disease, Myocardial Injury | Phase 4 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 140 | 2026-08-01 | 2026-07-30 |
| Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery Cardiac surgey - Valve Heart Disease, Coronary Artery Disease | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 10000 | 2026-06-25 | 2026-06-23 | |
| CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) CTCA - Coronary Heart Disease | Not applicable | Recruiting | Queen Mary University of London | 1000 | 2026-04-16 | 2026-06-05 |
| Timing of Endoscopy in Coronary Heart Disease Patients Taking Antiplatelet Drugs With Acute Non-variceal Upper Gastrointestinal Bleeding Urgent Endoscopy (Within 12 Hours of Admission), Early Endoscopy (12-24 Hours After Admission) - Acute Non-variceal Upper Gastrointestinal Hemorrhage, Coronary Heart Disease | Not applicable | Not yet recruiting | Beijing Anzhen Hospital | 212 | 2026-04-01 | 2026-04-02 |
| A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease Yiyang Huoluo Decoction, conventional western medicine treatment - Coronary Heart Disease, Coronary Artery Disease | Phase 1 / Phase 2 | Recruiting | Xia Liang | 30 | 2026-01-16 | 2026-03-25 |
| Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD) Digital Remote Management Group - Coronary Heart Disease, Percutaneous Coronary Intervention | Not applicable | Not yet recruiting | Beijing Anzhen Hospital | 792 | 2026-01-01 | 2026-01-12 |
| Safety and Efficacy of DCB Therapy for de Novo Lesions Under the Guidance of QFR in CHD Patients (UNIQUE-DCB-I Study ) drug coated balloon - Coronary Heart Disease | Not applicable | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 220 | 2026-01-01 | 2025-05-31 |
| Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study ) drug coated balloon, drug eluted stent - Coronary Heart Disease | Not applicable | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 220 | 2026-01-01 | 2025-05-31 |
| Gamification to Increase Mobility in the Hospital Gamification Intervention - Coronary Artery Disease, Coronary Heart Disease | Not applicable | Withdrawn | University of Pennsylvania | 2026-01-01 | 2025-12-30 | |
| A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography BioFreedom™, Xience - Coronary Heart Disease, Acute Coronary Syndrome | Not applicable | Recruiting | China National Center for Cardiovascular Diseases | 60 | 2025-12-10 | 2026-04-06 |
| Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction Yangxinshi tablet, Blank control - Coronary Heart Disease, Cardiac Dysfunction | Phase 4 | Recruiting | SPH Qingdao Growful Pharmacetical Co.,Ltd | 2708 | 2025-11-06 | 2025-11-25 |
| "Nutrition Education by Nurses in Patients After Coronary Artery Bypass Grafting: Effect on Patients' Dietary Pattern, Adherence and Clinical Outcomes" Patients of Group A and B both are filling out the questionnaire "Mediterranean diet questionnaire (MEDAS)", Patients of Group A and B both are filling out the "Mini Nutritional Asessment" questionnaire, Patients of Group A and B both are filling out "Nottingham Health Profile Scale" questionnaire - Coronary Heart Disease | Not applicable | Not yet recruiting | Hellenic Mediterranean University | 160 | 2025-10-01 | 2025-09-15 |
Showing 20 of 518. Sign in to see all of them.
Coronary Disease (518) · Cardiovascular Diseases (53) · Coronary Artery Disease (50) · Diabetes Mellitus (38) · Angina Pectoris (32) · Atherosclerosis (30) · Stroke (26) · Heart Failure (25) · Diabetes Mellitus, Type 2 (22) · Myocardial Infarction (21) · Dyslipidemias (19) · Hypercholesterolemia (19) · Myocardial Ischemia (19) · Hypertension (17) · Depression (15)
Vascular Diseases (516) · Heart Diseases (513) · Myocardial Ischemia (499) · Cardiovascular Diseases (465) · Pathological Conditions, Signs and Symptoms (128) · Nutritional and Metabolic Diseases (96) · Metabolic Diseases (92) · Arteriosclerosis (79) · Arterial Occlusive Diseases (78) · Pathologic Processes (74) · Signs and Symptoms (69) · Glucose Metabolism Disorders (61) · Endocrine System Diseases (55) · Neurologic Manifestations (52) · Pain (49)
Clopidogrel (17) · Atorvastatin (13) · Ezetimibe (12) · Aspirin (11) · Rosuvastatin Calcium (11) · Simvastatin (10) · Exercise (8) · 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (6) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (6) · Ticagrelor (6) · dalcetrapib (6) · Saline Solution (4) · Blood Specimen Collection (3) · Drug-Eluting Stents (3) · Fenofibrate (3)
China National Center for Cardiovascular Diseases (13) · AstraZeneca (12) · CardioDx (11) · Deutsches Herzzentrum Muenchen (11) · Ottawa Heart Institute Research Corporation (9) · University of Edinburgh (9) · Beijing Anzhen Hospital (8) · China Academy of Chinese Medical Sciences (7) · Chinese Academy of Medical Sciences, Fuwai Hospital (6) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (6) · Hoffmann-La Roche (6) · Nanjing First Hospital, Nanjing Medical University (6) · The First Affiliated Hospital with Nanjing Medical University (6) · University College, London (6) · Washington University School of Medicine (6)
China (123) · United States (83) · Germany (51) · United Kingdom (45) · Canada (31) · Denmark (16) · Italy (13) · Spain (13) · Netherlands (12) · Switzerland (12) · France (10) · Norway (10) · Sweden (10) · Austria (9) · Australia (7)
Harlan M Krumholz, M.D., S.M. (5) · Lixin Jiang, M.D., Ph.D. (5) · Adnan Kastrati, MD (4) · Julinda Mehilli, MD (4) · Michael Zapien, MS (4) · Yan M Xie, BA (4) · Albert Schoemig, MD (3) · Hyuk-Jae Chang, MD, PhD (3) · Stefan Esser, MD (3) · Bernhard Foger, MD (2) · Chao Gao, MD, Ph.D. (2) · Christoph Herrmann-Lingen, Prof. Dr. (2)
PMID 18783301, PMID 17666313, PMID 20024643, PMID 20136164, PMID 20573750, PMID 24667535, PMID 16183552, PMID 17898099, PMID 18305915, PMID 18557952, PMID 19723613, PMID 20002869, PMID 20739268, PMID 21450595, PMID 21764468, PMID 22027640, PMID 22254197, PMID 22263674, PMID 22345126, PMID 24529158, PMID 25119856, PMID 25252696, PMID 25614280, PMID 25828395, PMID 29579607, PMID 35147767, PMID 10223017, PMID 10438259, PMID 10527232, PMID 11028480, PMID 11426357, PMID 11456079, PMID 12117730, PMID 12456232, PMID 12595539, PMID 12607706, PMID 14663300, PMID 14993129, PMID 15172398, PMID 15257881, PMID 15791442, PMID 15826439, PMID 15982594, PMID 16105989, PMID 16554527, PMID 16644317, PMID 16825842, PMID 16845896, PMID 16846327, PMID 17084252
R01HL050420 (2), 2008 (1), 2019 (1), 2023 (1), P50HL083813 (1), R01AT000226 (1), R01HL093374 (1), R01HL106228 (1), R01HL108160 (1), R01HL141609 (1), R15NR010923 (1), R21AG081720 (1), U01DE013940 (1), U01GM074518 (1), U48DP002658 (1)